Anti-infliximab antibodies (also called antibodies to infliximab, or ATI) are proteins your immune system makes against the drug, which is itself an antibody. They can speed up how fast infliximab (Remicade and its biosimilars) leaves your blood and sometimes block its action. A positive result is a reason for a closer look, not an automatic verdict, and what happens next depends on your drug level, how large the antibody signal is, and how you feel. This article covers what clinicians consider after that result, not whether the drug has failed, and nothing here is advice to start, stop or change any medicine.
A note on sources: we read the abstracts or full texts of every paper cited here, and for the 2017 AGA guideline we cite a published commentary that summarizes its decision tool, because we could not open the guideline's full text. Most evidence on antibody rescue strategies is small and observational, and we say so where it applies.
What does it mean when your infliximab antibody test comes back positive?
A positive result means your blood contains antibodies that bind infliximab. It does not tell you, on its own, whether the drug still works. Doctors read it alongside your trough level (the amount of drug in your blood just before the next infusion), your inflammation markers, and your symptoms.
This is where infliximab is different from most medicines you take. Biologics are large proteins, and the immune system can treat them as foreign. The US label for Remicade says treatment can be associated with antibody development, and that people who became antibody-positive were roughly two to three times as likely to have an infusion reaction as those who were negative (Remicade US label). The same label notes that a newer drug-tolerant assay is about 60-fold more sensitive than the original method, which is one reason different studies report very different antibody rates.
An international expert panel on therapeutic drug monitoring (TDM) agreed unanimously that when the trough drug concentration is adequate, antibodies are unlikely to be clinically relevant (Papamichael 2019). That single statement explains why the same word, "antibodies", can mean "nothing to worry about yet" for one person and "this drug is being cleared too fast" for another.
If you want the broader background on why antibodies form and how often they appear for each biologic, we cover it in what it means when a biologic stops working. If you are wondering why your clinic orders so many blood tests in general, see why you need blood tests on a biologic. This article starts after the result lands and deals with the practical next steps.
Why did I get antibodies to infliximab?
Antibodies are common with infliximab, and forming them is not something you did wrong. Contributing factors in the research include the drug being given without an immunomodulator, long gaps between doses or episodic dosing, and the individual immune response. Many people who form antibodies took every dose on time.
Some of the oldest data come from the era when infliximab was given only when symptoms flared. In a Belgian cohort of 174 people with Crohn's disease on this on-demand schedule, antibodies were found in 55%. They were found in 46% of people who also took an immunomodulator (azathioprine or methotrexate) against 73% of people who did not, and the two immunomodulators performed similarly (Vermeire 2007).
A randomized trial from the same period (Farrell and colleagues) found that having a second infusion within eight weeks of the first, and taking a concurrent immunosuppressant, both lowered the odds of antibody formation. In that study, all seven people who had serious infusion reactions were antibody-positive (Farrell 2003).
The SONIC trial shows why combination treatment became common. Among 508 people with moderate to severe Crohn's disease who had not had immunosuppressants or biologics before, 56.8% of those on infliximab plus azathioprine were in steroid-free remission at week 26, compared with 44.4% on infliximab alone and 30.0% on azathioprine alone (Colombel 2010). Antibody formation was only one piece of that picture, and the trial did not tell us what to do once antibodies have already appeared.
In r/CrohnsDisease, the thread "Infliximab antibodies, what did you do?" shows how varied the picture is: some people were put on a thiopurine or methotrexate, some had their schedule changed, and some were moved to a different biologic, all after hearing the same words from their doctors (r/CrohnsDisease thread). These are individual stories, not evidence that any option works, but they show why the first step is the same for everyone: understand your own numbers.
How do doctors tell a low-titer result from a high-titer one?
Titer is the amount of antibody in your blood, and clinicians separate low-level from high-level results because they lead to different options. There is no single universal cut-off, because each lab's assay uses its own units and its own scale.
The 2019 international consensus gave assay-specific examples for infliximab at trough: a high titer is about 10 U/mL on the ANSER assay, and about 200 ng/mL on RIDAscreen and on the InformTx/LISA Tracker assay. For other assays the panel stated there was insufficient data to define a high-titer cut-off (Papamichael 2019).
An earlier Israeli study of 330 loss-of-response events used a different approach: antibody levels above 9 microgram per mL equivalents for infliximab identified people who did not respond to a higher drug dose, with 90% specificity (Yanai 2015). That is a different assay and different units, so the two numbers cannot be compared directly.
| What you may see on a report | What it usually reflects | Often considered alongside |
|---|---|---|
| Antibody negative, drug level low | Drug being cleared fast for another reason, or a dosing gap | Inflammation, albumin, timing of the draw |
| Antibody low-level, drug level adequate | Antibody present but drug still exposed | Symptoms, CRP or calprotectin, repeat test |
| Antibody low-level, drug level low or undetectable | Antibody may be speeding clearance | Dose, interval, immunomodulator, repeat test |
| Antibody high-titer, drug level undetectable | Antibody likely neutralizing or clearing most drug | Change of therapy, per the 2019 panel |
| Antibody positive once, then negative | Transient antibody | Often no change, with monitoring |
Do not use this table to interpret your own result. It describes the logic clinicians use, not a calculator. The labs differ, and so do the thresholds, which is why trends are best compared within the same lab and assay. Our blood tests article goes into how drug-level results differ between labs.
Why does timing of the blood draw matter?
Drug levels are meant to be drawn at trough, just before the next infusion, because the drug is at its lowest then. Antibody tests that are not drug-tolerant can also be affected by drug in the sample, which can hide antibodies. A common theme in the r/CrohnsDisease thread above is that people noticed the result changed depending on when the sample was taken and which lab ran it. That matches the label's statement that the original assay can underestimate antibody formation because it is subject to interference by drug in the blood (Remicade US label). If you are unsure when your sample was taken relative to your infusion, it is worth asking your team to note it on the request.
Do infliximab antibodies always go away or always stay?
Neither. Some antibodies are transient and some are sustained, and telling them apart is the main reason clinicians repeat the test rather than switching immediately.
A Belgian study measured infliximab antibodies repeatedly in 90 people with IBD and found antibodies in 53. In 15 of the 53 (28%) they disappeared over time, and in 38 (72%) they persisted. Among those with sustained antibodies, 26 of 38 (68%) had to stop infliximab, compared with 2 of 15 (13%) with transient antibodies. The authors recommended measuring antibodies when the drug level is low or undetectable, and following up positive results over consecutive time points (Vande Casteele 2013).
A French prospective cohort of 93 people found the same pattern from a different angle. Stable antibodies, defined as two consecutive results above 20 ng/mL, were independently linked with loss of response (hazard ratio 3.77), while transient antibodies were not (Roblin 2015).
A pre-existing antibody is a different matter again. In the UK PANTS cohort, about 6.3% of 1,525 people had antibodies to infliximab before ever receiving it. None of the detected antibodies neutralized the drug in the lab, and they were not associated with drug levels, infusion reactions or response at weeks 14 or 54 (Nice 2025). So an antibody finding is not always the same thing as anti-drug immunity.
What options do clinicians consider after an antibody result?
Clinicians generally weigh three directions: keeping infliximab and adjusting it, adding or changing a partner medicine, or moving to a different drug. Which one fits depends on your drug level, antibody titer, inflammation, history and preferences. The options below describe what the literature reports, not what you should ask for.
A published commentary on the 2017 American Gastroenterological Association (AGA) guideline summarizes the accompanying decision tool this way: people with a low or undetectable trough and a negative or low-titer antibody may benefit from dose escalation or adding an immunomodulator, while those with a low or undetectable trough and a high-titer antibody may benefit from switching within or outside the drug class. For those with a trough at or above target who are still symptomatic, the tool suggests that switching to a different class may help (Su 2017). The same commentary notes that the AGA made no recommendation on routine proactive testing in people whose IBD is quiet.
| Option | Evidence summary | Caveats |
|---|---|---|
| Adjust dose or interval | A pediatric Crohn's cohort found dose adjustment resolved antibodies in 12 of 32 (37.5%), with drug levels recovering (Colman 2022) | Children, observational; antibodies were low-level in most |
| Add an immunomodulator | Small series report antibody clearance and restored response, including all 5 in one report (Ben-Horin 2013) and 8 of 12 in another (Kothari 2017) | Tiny, retrospective, results selected; an adalimumab series cleared antibodies in 48% (Ungar 2017) |
| Switch to another anti-TNF | A meta-analysis found remission in 43% after infliximab failure in Crohn's, 45% after secondary loss of response (Gisbert 2015) | Depends on why the first drug failed |
| Switch to a different class | Suggested by guidance when drug levels are adequate but disease is active (Su 2017) | Far less is known about antibody-driven failure specifically |
Four points sit behind that table.
First, low-level antibodies "can sometimes be overcome", in the words of the 2019 panel, while high-titer antibodies in the absence of detectable drug "require a change of therapy" (Papamichael 2019). The wording is deliberately modest: sometimes, not usually.
Second, most evidence for rescue strategies is small and observational. The Kothari series included just 12 people, and Ben-Horin 5. People who do well in such reports are more likely to be written up. Take the percentages as "this has been seen", not "this will happen to you".
Third, testing may help a clinician choose rather than guarantee a better outcome. In a Danish randomized trial of 69 people with Crohn's who lost response to infliximab, treatment chosen by drug and antibody levels produced a similar response rate at week 12 to routine dose intensification (58% versus 53%), at about 34% lower cost (Steenholdt 2014). Matching treatment to the cause avoided giving more of a drug that was unlikely to help.
Fourth, the decision is not only pharmacological. Your disease type, past surgeries, other medicines, pregnancy plans, access and insurance, and what has already been tried all enter the discussion. For what comes after a second or third biologic, see what to do when all biologics fail in Crohn's and how often people switch biologics.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
What do people in r/CrohnsDisease report after an antibody result?
A recurring theme is that people hear about the same few directions: adding azathioprine, 6-mercaptopurine or methotrexate, tightening the schedule, or switching drugs. A second theme is lab confusion, where results changed between labs or depending on the draw time. A third is that some people describe a severe reaction and then a switch, while others describe antibodies that never caused a problem (r/CrohnsDisease thread on adalimumab antibodies, r/CrohnsDisease thread on antibodies to infliximab).
These stories are useful as vocabulary, so you know the questions to ask. They are not a guide to what will work for you, because each person's drug level, titer, disease location and history differ. Reading that someone "stopped the partner drug after a year" is not a reason to expect the same, or to stop anything yourself.
What should I ask my gastroenterologist after a positive result?
Go in with a short list of questions, because the answers shape the plan. Write them down beforehand, since appointments are short and results are easy to forget.
- Which lab and which assay produced the result, and was the sample taken at trough?
- What was my trough drug level, and was it low, adequate or undetectable?
- Is the antibody low-level or high-titer on this lab's scale, and what is the cut-off?
- Will you repeat the test, and when? What would a repeat result change?
- What are my CRP, fecal calprotectin and albumin showing, and has anything been done to confirm inflammation?
- If the plan is to adjust the current treatment, what will we monitor, and for how long, before deciding it did or did not work?
- Are there reasons my situation is different (other medicines, a recent gap in infusions, previous reactions)?
- What would trigger a change of drug?
Our guide to preparing for a GI appointment has more general prompts, and the article on stopping Crohn's medication in remission explains why those decisions are made with your team rather than alone.
What infusion reactions should I watch for?
Antibodies are linked to more infusion reactions, so it is sensible to know the warning signs and tell your nurse about them. This is not a self-diagnosis list: it is a list of things to report without waiting for your next visit.
During or just after an infusion, tell the infusion nurse at once about throat tightness, trouble breathing, swelling of the face or lips, widespread hives, chest discomfort, dizziness or a sudden feeling of being unwell. If symptoms start after you leave, treat difficulty breathing or facial swelling as an emergency and seek urgent care.
The US label also describes reactions after Remicade was restarted following an extended period without treatment, with symptoms such as fever, rash, headache, sore throat, muscle and joint pain, and swelling of the hands and face. It notes these were associated with a marked increase in antibodies and loss of detectable drug, and says Remicade should be discontinued for severe hypersensitivity reactions (Remicade US label). The decision to continue after any reaction belongs to the prescriber. A first infusion walk-through is in what to expect at your first biologic infusion.
Mild reactions are different from serious ones, and a record that distinguishes them helps. Note when the reaction began relative to the infusion, how long it lasted, and what the nurse did.
How do I track symptoms around infusions when antibodies are suspected?
A good log lets your team separate "the drug is leaving my blood too fast" from "this is inflammation" and from "this is something else". The pattern across the weeks between infusions is often more informative than any single day.
Record these, in the order they are easiest to capture:
- Infusion date and time, and the date of the next one. Include any delay or rescheduling, and the reason.
- Symptoms before and after each infusion. Stool frequency and consistency, urgency, pain, blood, fatigue, fever. Note whether you feel well for the first weeks and worse near the end of the cycle, because that pattern can reflect a falling drug level.
- Reactions. What happened, when, and what was done.
- Missed or late doses of your partner drug, if you take one. Gaps are one of the things a team will ask about.
- Lab results. Trough level, antibody result, CRP, calprotectin, albumin, with the date and the lab name.
- Other changes. New medicines, steroids, antibiotics, infections, travel, big stress events, surgery.
Do not use the log to decide whether a drug is working, and do not change any treatment because of what it shows. Its job is to make the next appointment short, specific and useful. The flare guide explains how to separate a flare from a bad day, and the article on whether a symptom tracker can predict a flare covers what logs can and cannot show.
Clairop's one-page GI report can sit beside your symptom trend and medication adherence so that a lab result and how you felt around it are side by side; see how it works for what the report contains. It is a record you keep, not a diagnostic tool. If you are comparing tools, our apps for Crohn's disease list sets them out.
Can infliximab work again after antibodies?
Sometimes, but the honest answer is that evidence is mixed and individual. In the pediatric Crohn's cohort, dose adjustment resolved antibodies in 37.5% of those treated, and a maximum antibody level of 99 ng/mL or below predicted resolution (Colman 2022). In the Belgian study, some antibodies simply disappeared (Vande Casteele 2013). In other people they persist, and a change of drug follows.
Switching to another anti-TNF after infliximab can work, but results depend on the reason for failing the first drug. In a meta-analysis of 46 studies, a second anti-TNF induced remission in 43% of people with Crohn's disease who had failed infliximab, and the remission rate was highest when the reason was intolerance (61%) and lowest after primary failure (30%) (Gisbert 2015). Antibody-driven failure was not separated out in that summary, so it should not be read as a prediction for antibody-positive people specifically.
There is no promise in either direction, and anyone who offers one is overselling. What can be said is that an antibody result narrows the list of explanations, which helps a team choose among the options rather than guess.
What are the common myths about infliximab antibodies?
Several beliefs circulate that the evidence does not support. Correcting them can reduce unnecessary fear.
- "Antibodies mean the drug has failed." Not necessarily. When drug levels are adequate, antibodies are unlikely to matter clinically per the 2019 consensus, and transient antibodies were not linked to loss of response in the French cohort (Roblin 2015).
- "A single positive test is final." Repeat testing exists because 28% of antibody-positive people in the Belgian study cleared them.
- "All labs give the same number." They do not; units, assays and thresholds differ, and the label says the original assay can underestimate antibodies.
- "I caused this by missing an infusion." Antibodies occur in people who never miss a dose. Gaps may contribute for some, but they are not the only route.
- "Adding a second drug always fixes it." The reports are small and the success rates varied (48% in the adalimumab series, higher in two tiny infliximab series).
- "I should push for the newest drug." The right next step depends on your drug level and inflammation, and your team has the full picture.
When should I contact my IBD team promptly?
Contact your team without waiting if symptoms return between infusions, or if you notice any of the following. Do not wait for the next scheduled test.
- Blood in your stool, new or worsening, or persistent diarrhea
- Fever, night sweats or chills
- Unexplained weight loss
- Severe or worsening abdominal pain, or a hard, swollen abdomen
- Signs of an infusion reaction, as above
- New joint pain, rash or eye pain
- Signs of infection while on an immunosuppressant, such as a persistent fever or a sore throat that will not clear
Throat swelling or difficulty breathing is an emergency: call emergency services.
What is the short version?
A positive infliximab antibody result is information for a decision, not the decision itself. Your team will look at the antibody level, your drug level, your inflammation markers and your symptoms, and often repeat the test. Low-level antibodies can sometimes be overcome; high-titer antibodies with no detectable drug usually lead to a change of therapy. The evidence for each rescue strategy is small and mostly observational, which is why individual advice matters.
The most useful thing you can do between now and your next appointment is keep a clean record: infusion dates, symptoms, reactions, delays and lab values. Bring your questions, ask which lab and which assay, and let your IBD team decide the next step. No forum thread, including the ones we linked, can do that for you.




